secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2023-09-20T23:59:59+00:00
Accession:  0001193125-23-238127
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health regains Nasdaq compliance after reverse split; delisting averted
-----------------------------------------------------------------------------

- Nasdaq notified Tivic on Sept 15, 2023 that bid price deficiency is cured.
- Company effected 1-for-100 reverse stock split on Aug 21, 2023 to cure deficiency.
- Nasdaq cancelled the hearing and reversed its delisting determination.
- Common stock continues trading on Nasdaq Capital Market under TIVC.
- No financial impact disclosed beyond compliance status.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000119312523238127/0001193125-23-238127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000119312523238127/d556941d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-238127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer